GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2007

Respironics’ Device Used in Clinical Evaluation Of Interferon Gamma to Treat Idiopathic PF Patients

  • Respironics inked an agreement with The State University of New York (SUNY) and New York University School of Medicine (NYU) to utilize the I-neb Adaptive Aerosol Delivery (AAD®) system for clinical evaluation of aerosolized Interferon Gamma for the treatment of idiopathic pulmonary fibrosis (IPF). The clinical trial will take place over a two-year time period.

    The I-neb device uses Respironics’ AAD technology, which reportedly is an “intelligent” inhalation technology that continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. The result is precise, reproducible dosing of medication to each patient, regardless of his/her breathing pattern, according to the company.

    The I-neb AAD System is Respironics’ third generation AAD System and is smaller, quieter and more portable than earlier product generations, notes a company spokesperson. The device weighs less than eight ounces and can be carried in a purse, pocket or briefcase. The I-neb device also provides audible and visual feedback to the patient informing the patient when the treatment is complete.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?